Genmab — December 2020
-
Haven‘t they decided on the optimal dose for Glofitamab? They call it step up dosing...
-
Yes sure
-
-
Next steps
While the burning question was whether or not the novel targets are better used before or after BCMA, the more practical solution is to simply combine the mechanisms. In fact, Johnson & Johnson is already at work on that front, with a Phase I study exploring the combination of talquetamab and the BCMA bispecific antibody teclistamab.
-
There’s also preclinical data supporting the role of CD38-targeting agents in T-cell expansion, which suggests that front-line therapy Darzelex (daratumumab) could help potentiate the T-cell engaging effect of antibodies like talquetamab. Accordingly, Johnson & Johnson is also evaluating that combination in a Phase I trial- along with various combinations of teclistamab and pomalidomide- which could represent its best opportunity for leapfrogging the BCMA drug class.
-
Tak Sukkeralf. Kombinere T&T må trods alt give ca. 10% til Genmab
-
Godt scenarie
-
Henrykt storbank efter lægemøde: Genmabs aktie kan blive 5750 kr værd
Genmab har fremlagt data på en konference i weekenden, der imponerer analytikerne Genmabs investorer har endnu engang grund til at drømme stort, efter at selskabet i weekenden har fremlagt nye data me
borsen.dk (borsen.dk)
-
Jeg ved det ikke, men jeg skifter til den lige om lidt .-)
-
-
Jeg har ikke adgang mere, men jeg hå¨ber at der er nogle der har og kan give et par stikord.
-
Epcoritamab topsalg på 4 mia $
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind